1. Home
  2. MTEK vs HIND Comparison

MTEK vs HIND Comparison

Compare MTEK & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.15

Market Cap

11.7M

Sector

N/A

ML Signal

HOLD

HIND

Vyome Holdings Inc.

HOLD

Current Price

$1.89

Market Cap

13.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
HIND
Founded
2008
2017
Country
Israel
United States
Employees
14
18
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
13.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
MTEK
HIND
Price
$1.15
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
104.3K
22.2K
Earning Date
05-12-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$1.75
52 Week High
$4.27
$12.87

Technical Indicators

Market Signals
Indicator
MTEK
HIND
Relative Strength Index (RSI) 38.20 35.76
Support Level $1.08 $1.75
Resistance Level $1.50 $2.36
Average True Range (ATR) 0.13 0.13
MACD 0.00 -0.01
Stochastic Oscillator 21.22 13.03

Price Performance

Historical Comparison
MTEK
HIND

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: